Advanced NSCLC patients harbouring HER2 mutations have a worse prognosis (median survival: 1.9–2.3 years) [3, 7], compared with those harbouring EGFR or ALK mutations. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.